Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.45 |
| ▸ | F2 | P00734 | 5/20 | 0.45 |
| ▸ | PLAU | P00749 | 5/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23782916 | 0.92 | ELANE (0.43) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL22445983 | 0.89 | ELANE (0.41) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL25444558 | 0.88 | CNR2 (0.42) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL3517132 | 0.86 | ELANE (0.41) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL22446017 | 0.85 | ELANE (0.39) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL23783187 | 0.85 | ELANE (0.46) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL29643983 | 0.85 | ELANE (0.46) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL22446031 | 0.85 | MAPT (0.41) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL3517141 | 0.84 | CNR2 (0.45) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL2470918 | 0.84 | CNR2 (0.45) | ELANEF2PLAUCTRB1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| CN-100369899-C | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | CN | disclosed |
| CN-1642922-A | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2005-07-20 | — | — | CN | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | ELANE 3188/4885F2 4207/4885PLAU 3681/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | ELANE 3153/4885F2 4461/4885PLAU 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.